Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific

Jan M. Bell, John D. Turnidge, Charles H. Ballow, Ronald N. Jones, J. Turnidge, R. Benn, L. Grayson, J. Faoagali, K. Christiansen, A. Cheng, D. Tsang, S. Kohno, K. Yamaguchi, M. Kahu, J. H. Woo, K. W. Choi, K. W. Lee, M. Yeo, G. Kumarasinghe, Po Ren HsuehY. C. Liu, H. S. Leu

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)


Multiresistance to antimicrobial agents is common in staphylococci and pneumococci isolates in the Western Pacific region. The activity of linezolid, a new oxazolidinone, was evaluated against a spectrum of Gram-positive species collected in the region. Eighteen laboratories from six countries in the Western Pacific examined the linezolid susceptibility of 2143 clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci (CoNS) and Enterococcus spp. using broth microdilution or disc diffusion methodology. For Streptococcus pneumoniae (n=351) and other streptococci (n=83), Etest (AB Biodisk, Solna, Sweden) strips were used. Results were compared with other common and important antimicrobials. Linezolid-resistant strains were not detected among streptococci or staphylococci, including a significant proportion of S. aureus strains that were multiresistant. Almost all enterococci, including 14 vancomycin-resistant Enterococcus faecium, were linezolid susceptible. A small proportion of enterococci (0.8%) were intermediate to linezolid, and one strain of Enterococcus faecalis had a zone diameter of 20 mm (resistant). The linezolid MIC ranges (MIC90) of those strains tested by broth microdilution or Etest were: 1-4 mg/L (2 mg/L) for S. aureus, 0.5-4 mg/L (2 mg/L) for CoNS, 0.5-4 mg/L (2 mg/L) for Enterococcus spp., 0.12-2 mg/L (1 mg/L) for S. pneumoniae and 0.25-2 mg/L (1 mg/L) for Streptococcus spp. There was no difference in linezolid susceptibility between countries or between multiresistant and susceptible strains of each species monitored.

Original languageEnglish
Pages (from-to)339-345
Number of pages7
JournalJournal of Antimicrobial Chemotherapy
Issue number2
Publication statusPublished - 2003 Feb 1

Bibliographical note

Funding Information:
This study was supported by an educational/research grant from Pharmacia and Upjohn (Kalamazoo MI, USA). ZAPS Western Pacific Regional Participants are as follows: Australia: J. Turnidge (Women’s and Children’s Hospital, Adelaide); R. Benn (Royal Prince Alfred Hospital, Sydney); L. Grayson (Monash Medical Centre, Melbourne); J. Fao-agali (Royal Brisbane Hospital, Brisbane); K. Christiansen (Royal Perth Hospital, Perth). China: A. Cheng (Prince of Wales Hospital, Hong Kong); D. Tsang (Queen Elizabeth Hospital, Hong Kong). Japan: S. Kohno (Nagasaki University School of Medicine, Nagasaki); K. Yamaguchi (Toho University, Tokyo); M. Kahu (Tohoku University, Aoba-ku Sendai). Korea: J. H. Woo (University of Ulsan, Seoul); K. W. Choi (Seoul National University Hospital, Seoul); K. W. Lee (Yonsei University, Seoul). Singapore: M. Yeo (Singapore General Hospital); G. Kumarasinghe (National University Hospital). Taiwan: Po-Ren Hsueh (National Taiwan University Hospital, Taipei); Y. C. Liu (Veterans General Hospital, Kaohsiung); H. S. Leu (Chang-Gung Memorial Hospital, Taoyuan).

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific'. Together they form a unique fingerprint.

Cite this